MedTrace Logo

Binding of Foliglurax to Regions in the Brain in Healthy Participants and in Patients With Parkinson's Disease (PD)

NCT04175132 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2020-12-09

No results posted yet for this study

Summary

A study to learn how foliglurax binds in regions of the brain

Conditions

  • Healthy
  • Parkinson Disease

Interventions

DRUG

foliglurax

Capsules of 20/80 mg foliglurax, orally. Single doses of 20-240 mg

DRUG

foliglurax

Capsules of 20/80 mg foliglurax, orally. Single doses of 20-160 mg

Sponsors & Collaborators

  • H. Lundbeck A/S

    lead INDUSTRY

Principal Investigators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
50 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-11-12
Primary Completion
2020-03-03
Completion
2020-03-10

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04175132 on ClinicalTrials.gov